Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.

Autor: Fiskus W; MD Anderson Cancer Center, Houston, Texas, United States., Mill CP; MD Anderson Cancer Center, Houston, Texas, United States., Bose P; University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Masarova L; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Pemmaraju N; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Dunbar A; MD Anderson Cancer Center, Houston, Texas, United States., Birdwell C; MD Anderson Cancer Center, Houston, Texas, United States., Davis JA; MD Anderson Cancer Center, Houston, Texas, United States., Das K; UT MD Anderson Cancer Center, Houston, Texas, United States., Hou H; UT MD Anderson Cancer Center, Houston, Texas, United States., Manshouri T; MD Anderson Cancer Center, Houston, Texas, United States., Jain A; Baylor College of Medicine, Houston, Texas, United States., Malovannaya A; Baylor College of Medicine, Houston, Texas, United States., Philip K; MD Anderson Cancer Center, Houston, Texas, United States., Alhamadani N; MD Anderson Cancer Center, Houston, Texas, United States., Matthews A; MD Anderson Cancer Center, Houston, Texas, United States., Lin K; MD Anderson Cancer Center, Houston, Texas, United States., Flores L; UT MD Anderson Cancer Center, Houston, Texas, United States., Loghavi S; The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States., DiNardo CD; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Su X; MD Anderson Cancer Center, Houston, Texas, United States., Rampal RK; Memorial Sloan-Kettering Cancer Center, New York, New York, United States., Bhalla KN; MD Anderson Cancer Center, Houston, Texas, United States.

Publikováno v: Blood [Blood] 2024 Nov 19. Date of Electronic Publication: 2024 Nov 19.

Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.

Autor: Birdwell CE; M.D. Anderson Cancer Center, The University of Texas, Houston, TX, 77030, USA., Fiskus W; M.D. Anderson Cancer Center, The University of Texas, Houston, TX, 77030, USA., Kadia TM; M.D. Anderson Cancer Center, The University of Texas, Houston, TX, 77030, USA., Mill CP; M.D. Anderson Cancer Center, The University of Texas, Houston, TX, 77030, USA., Sasaki K; M.D. Anderson Cancer Center, The University of Texas, Houston, TX, 77030, USA., Daver N; M.D. Anderson Cancer Center, The University of Texas, Houston, TX, 77030, USA., DiNardo CD; M.D. Anderson Cancer Center, The University of Texas, Houston, TX, 77030, USA., Pemmaraju N; M.D. Anderson Cancer Center, The University of Texas, Houston, TX, 77030, USA., Borthakur G; M.D. Anderson Cancer Center, The University of Texas, Houston, TX, 77030, USA., Davis JA; M.D. Anderson Cancer Center, The University of Texas, Houston, TX, 77030, USA., Das K; M.D. Anderson Cancer Center, The University of Texas, Houston, TX, 77030, USA., Sharma S; TGen, Phoenix, AZ, 85004, USA., Horrigan S; Iterion Therapeutics, Houston, TX, 77021, USA., Ruan X; M.D. Anderson Cancer Center, The University of Texas, Houston, TX, 77030, USA., Su X; M.D. Anderson Cancer Center, The University of Texas, Houston, TX, 77030, USA., Khoury JD; University of Nebraska Medical Center, Omaha, NE, 68198, USA., Kantarjian H; M.D. Anderson Cancer Center, The University of Texas, Houston, TX, 77030, USA., Bhalla KN; M.D. Anderson Cancer Center, The University of Texas, Houston, TX, 77030, USA. kbhalla@mdanderson.org.

Publikováno v: Leukemia [Leukemia] 2024 Mar; Vol. 38 (3), pp. 545-556. Date of Electronic Publication: 2023 Dec 12.

Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.

Autor: Bataller A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Loghavi S; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gerstein Y; Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Bazinet A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Chien KS; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hammond D; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Short N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tang G; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Quesada A; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Patel KP; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Fiskus W; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Mill CP; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Bhalla K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Oran B; Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Publikováno v: American journal of hematology [Am J Hematol] 2023 Nov; Vol. 98 (11), pp. 1780-1790. Date of Electronic Publication: 2023 Sep 04.

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1.

Autor: Fiskus W; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mill CP; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Birdwell C; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Davis JA; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Das K; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Boettcher S; University of Zurich and University Hospital Zurich, CH-8091, Zurich, Switzerland., Kadia TM; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., DiNardo CD; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Takahashi K; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Loghavi S; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Soth MJ; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Heffernan T; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., McGeehan GM; Syndax Pharmaceuticals, Waltham, MA, USA., Ruan X; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Su X; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Vakoc CR; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 11724, USA., Daver N; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bhalla KN; The University of Texas MD Anderson Cancer Center, Houston, TX, USA. kbhalla@mdanderson.org.

Publikováno v: Blood cancer journal [Blood Cancer J] 2023 Apr 13; Vol. 13 (1), pp. 53. Date of Electronic Publication: 2023 Apr 13.